Clinical Trial Update: Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial of lenalidomide with doxorubicin liposome in recurrent ovarian, fallopian tube, or primary peritoneal cancer; the study is terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• DOXORUBICIN HYDROCHLORIDE LIPOSOME (DOXORUBICIN HYDROCHLORIDE)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-01-18